- Home
- CCK vs MRNA Comparison
CCK vs MRNA Comparison
Compare CCK & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCK | MRNA |
|---|---|---|
| Founded | 1906 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 11.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CCK | MRNA |
|---|---|---|
| Price | $110.46 | $41.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 12 |
| Target Price | ★ $121.93 | $31.09 |
| AVG Volume (30 Days) | 1.3M | ★ 14.3M |
| Earning Date | 02-04-2026 | 02-13-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 79.72 | N/A |
| EPS | ★ 6.38 | N/A |
| Revenue | ★ $12,365,000,000.00 | $2,232,000,000.00 |
| Revenue This Year | $2.87 | N/A |
| Revenue Next Year | $2.44 | $5.82 |
| P/E Ratio | $17.69 | ★ N/A |
| Revenue Growth | ★ 4.78 | N/A |
| 52 Week Low | $75.98 | $22.28 |
| 52 Week High | $115.85 | $55.20 |
Technical Indicators
Market Signals| Indicator | CCK | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.04 | 52.96 |
| Support Level | $110.05 | $40.08 |
| Resistance Level | $115.85 | $43.85 |
| Average True Range (ATR) | 2.67 | 3.45 |
| MACD | 0.75 | -1.04 |
| Stochastic Oscillator | 64.32 | 11.08 |
Price Performance
Historical ComparisonAbout CCK Crown Holdings Inc.
Crown Holdings is one of the world's largest producers of metal packaging. The company manufactures beverage cans, metal food cans, and closures as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.